Results for tag: "Ibritumomab Tiuxetan"

Ibritumomab Tiuxetan is a monoclonal antibody used in the treatment of certain types of leukemia. It is used in combination with chemotherapy and radiation therapy to treat B-cell non-Hodgkin's lymphoma. The drug is administered intravenously and binds to a specific antigen on the surface of B-cells, which triggers the body's immune system to attack and destroy the cancer cells. Ibritumomab Tiuxetan is approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma. The Ibritumomab Tiuxetan market is a niche market, with a limited number of competitors. The market is dominated by a few large pharmaceutical companies, such as GlaxoSmithKline, Merck, and Bristol-Myers Squibb. These companies have invested heavily in research and development to develop new treatments for leukemia. Smaller companies, such as Immunomedics and ImmunoGen, are also active in the market, developing new treatments and therapies. Companies in the Ibritumomab Tiuxetan market include GlaxoSmithKline, Merck, Bristol-Myers Squibb, Immunomedics, and ImmunoGen. Show Less Read more